Equities research analysts expect BIONDVAX PHARMA/S (NASDAQ:BVXV) to report earnings of ($0.03) per share for the current quarter, Zacks reports. Zero analysts have made estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S posted earnings per share of ($0.11) during the same quarter last year, which suggests a positive year-over-year growth rate of 72.7%. The company is scheduled to announce its next earnings results on Tuesday, November 12th.

On average, analysts expect that BIONDVAX PHARMA/S will report full year earnings of ($0.08) per share for the current year. For the next year, analysts forecast that the firm will post earnings of ($0.07) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for BIONDVAX PHARMA/S.

Separately, ValuEngine raised BIONDVAX PHARMA/S from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th.

Shares of NASDAQ BVXV traded down $0.08 during mid-day trading on Friday, hitting $5.64. The company had a trading volume of 200 shares, compared to its average volume of 7,918. The company has a market capitalization of $36.95 million, a price-to-earnings ratio of -1.57 and a beta of 1.17. BIONDVAX PHARMA/S has a 1 year low of $3.51 and a 1 year high of $7.26. The stock’s 50-day moving average price is $5.96 and its 200-day moving average price is $6.01.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

Read More: What is a Derivative?

Get a free copy of the Zacks research report on BIONDVAX PHARMA/S (BVXV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.